Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2021 - 08 - 11 save search
Xeris Pharmaceuticals Announces FDA Acceptance of its IND Application for XeriSol™ Levothyroxine (XP-8121) for the Treatment of Hypothyroidism
Published: 2021-08-11 (Crawled : 22:00) - biospace.com/
XERS | $1.835 3.09% 960K
|
Health Technology
|
| O: 0.43%
H: 1.29%
C: 1.29%
treatment fda fda acceptance application
Radiotherapy Market Size to Reach USD 7.65 Billion in 2027 | Increasing Global Incidence of Cancer, Rising Use of Radiotherapy in Combination with Other Treatment Approaches are Some Key Factors Driving Industry Demand, says Emergen Research
Published: 2021-08-11 (Crawled : 14:15) - prnewswire.com
VRAY | $0.025 -39.9% -61.87% 110M
|
Health Technology
|
| O: 0.0%
H: 0.67%
C: -4.88%
ARAY | $2.24 3.23% 220K
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: -1.0%
treatment therapy cancer research iot merge
Plus Therapeutics to Present Data from Two Studies Supporting the Treatment of Leptomeningeal Metastases with Rhenium-186 Nanoliposome
Published: 2021-08-11 (Crawled : 14:15) - globenewswire.com
PSTV | News | $1.65 -0.6% 16K
|
Health Technology
|
| O: 0.0%
H: 24.06%
C: 11.23%
treatment
AcQMap 8, Acutus Medical’s Innovative Suite of Software Upgrades, Receives FDA Clearance and CE MarkEnhanced Software Automatically Identifies Regions of Interest During the Treatment of Complex Atrial Arrhythmias
Published: 2021-08-11 (Crawled : 13:15) - biospace.com/
AFIB | $0.169 0.84% 44K
|
Health Technology
|
| O: 0.63%
H: 1.04%
C: -0.41%
fda clearance treatment fda software ce mark trial clearance
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
Published: 2021-08-11 (Crawled : 13:00) - biospace.com/
LTRN | News | $5.84 2.1% 100K
|
Health Technology
|
| O: 10.01%
H: 0.41%
C: -11.34%
treatment fda cancer drug pancreatic pancreas granted grant designation pharma
Akouos Announces European Commission Designation of AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss as an Orphan Drug
Published: 2021-08-11 (Crawled : 12:00) - biospace.com/
AKUS | $13.29 1.07% 3.46%
|
Health Technology
|
| O: 3.16%
H: 0.0%
C: -5.9%
media treatment europe drug hearing loss designation
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M
|
AGBA | $2.74 119.2% 52M
|
Finance
CZOO | $9.07 81.76% 22M
|
EDBL | News | $6.56 74.47% 1.8M
|
MTC | $2.21 41.67% 5.6M
|
Technology Services
OPRT | News | $3.12 38.67% 11M
|
Finance
PALI | $6.59 33.67% 23M
|
Manufacturing
VNRX | $0.7945 32.42% 3.1M
|
Health Technology
MLEC | $1.81 29.29% 2.8M
|
n/a
BTCM | $3.45 27.78% 640K
|
Arts, Entertainment, and Recrea...
Your saved searches
Save your searches and get alerts when important news are released.